$NTFL DD Package: Underwrote LFIN which entitled them

New Post Public Reply Private Reply Replies (1) Message Board
SHEEPWOLF
3,774
$NTFL DD Package:

Underwrote LFIN which entitled them to buy 600k $LFIN shares at $7.50 each...they are now worth 10x that price

600k x $80(current price) = $48m THEY ARE CURRENT TRADING AT AN 11M MARKET CAP

COMPANY WEBSITE: http://network1.com/

Other recent transactions by company:

http://network1.com/recent-transactions/

LFIN IPO DOCUMENT: https://www.sec.gov/Archives/edgar/data/16996...7/pos9.htm

(1) We have entered into an Underwriting Agreement with Network 1 Financial Securities, Inc. (the “Underwriter”) to conduct this offering on a “best efforts” basis. We have agreed to pay the Underwriter a cash fee equal to (i) 7% of the gross proceeds from the first 3,000,000 shares ($15,000,000) sold in this offering and (ii) 3% of the gross proceeds from the sale of the last 7,000,000 shares ($35,000,000) sold in this offering. We have also agreed to issue the Underwriter warrants to purchase an amount of shares equal to 6% of the shares sold in this offering for $7.50 (150% of the offering price) per share exercisable from six-month date from the date of issuance until June 16, 2022, the fifth anniversary of the date this offering was qualified by the Securities and Exchange Commission. See “Plan of Distribution and Selling Security Holders” for more information on this offering and the underwriter arrangements.

We have agreed to pay the Underwriter a cash fee equal to (i) 7% of the gross proceeds from the sale of first 3,000,000 shares ($15,000,000) sold in this offering and (ii) 3% of the gross proceeds from the sale of the next 7,000,000 shares ($35,000,000) sold in this offering. The Underwriter may allow, and certain dealers may re-allow, a discount from the concession to certain brokers and dealers. After this offering, the initial public offering price, concession and reallowance to dealers may be changed by the representatives. No such change shall change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. The shares are offered by the Underwriter as stated herein, subject to receipt and acceptance by them and subject to their right to reject any order in whole or in part.

We have also agreed to pay the Underwriter a non-accountable expense allowance equal to 2% of the gross proceeds of the offering for the first 3,000,000 shares ($15,000,000) sold in this offering up to $300,000. In addition, the Company agrees to reimburse the Underwriter for expenses relating to the offering, including all actual fees and expenses incurred by the Underwriter in connection with the Underwriter’s “road show” expenses evidenced by invoices, and the fees and expenses of the Underwriter’s counsel which, in the aggregate shall not exceed $75,000, less the $25,000 payment previously paid by the Company to the Underwriter pursuant to the Engagement Agreement, dated June 30, 2017, between the Company and the Underwriter.

Underwriters Agreement:
https://www.sec.gov/Archives/edgar/data/16996...mended.htm


Recent Headlines:

https://insiderfinancial.com/network-1-financ...close-look

https://www.globenewswire.com/news-release/20...ASDAQ.html

"New York, NY, Sept. 06, 2017 (GLOBE NEWSWIRE) -- LongFin Corp. (NASDAQ:LFIN), today announced its initial public offering of 10,000,000 shares of its Class A common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the NASDAQ in October 2017, under the ticker symbol “LFIN”. Network 1 Financial Securities, Inc. is acting as lead book-running manager and underwriter for the offering."

credit too
Mrs. Claus for this DD
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles